Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Prediction and management of recurrent venous thromboembolism in patients with cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
491
Views
195
Downloads
Authors
Patients with cancer have an increased risk of venous thromboembolism (VTE), often even while on therapeutic dose of anticoagulation. Recent randomized controlled trials show that the 6-month rate of recurrent VTE is 5-8% during anticoagulation. Multiple risk factors are reported to be associated with recurrent cancer-associated thrombosis, including history of VTE, poor Eastern Cooperative Oncology Group performance status, metastatic diseases, and certain cancer types. Several risk assessment models are derived, but better validation is needed before clinical use. Management of patients with recurrent VTE while on anticoagulation is challenging. Necessary considerations include both the risk of further VTE recurrence and the risk of bleeding. In this review, we will summarize pertinent literature and provide suggestions on the management strategies in patients with recurrent cancer-associated thrombosis.
Downloads
Download data is not yet available.
Citations
1. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
2. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74. DOI: https://doi.org/10.1182/bloodadvances.2021004734
3. National Comprehensive Cancer Network [Internet]. NCCN guideline pane.l Cancer-Associated Venous Thromboembolic Disease. 2021
4. van Hylckama Vlieg MAM, Nasserinejad K, Visser C, et al. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. EClinicalMedicine 2023;64:102194. DOI: https://doi.org/10.1016/j.eclinm.2023.102194
5. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24. DOI: https://doi.org/10.1056/NEJMoa1711948
6. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-23. DOI: https://doi.org/10.1200/JCO.2018.78.8034
7. McBane RD, 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18:411-21. DOI: https://doi.org/10.1111/jth.14662
8. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607. DOI: https://doi.org/10.1056/NEJMoa1915103
9. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022;161:781-90. DOI: https://doi.org/10.1016/j.chest.2021.09.037
10. Abdulla A, Davis WM, Ratnaweera N, et al. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13. DOI: https://doi.org/10.1055/s-0040-1708481
11. Frere C, Farge D, Schrag D, et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2022;15:69. DOI: https://doi.org/10.1186/s13045-022-01289-1
12. Caiano L, Carrier M, Marshall A, et al. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost 2021;19:2468-79. DOI: https://doi.org/10.1111/jth.15435
13. Khan F, Tritschler T, Marx CE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J 2025:ehaf453. Online Ahead of Print. DOI: https://doi.org/10.1093/eurheartj/ehaf453
14. van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thromb Res 2018;163:41-6. DOI: https://doi.org/10.1016/j.thromres.2018.01.009
15. Otero R, Solier-Lopez A, Sanchez-Lopez V, et al. Biomarkers of venous thromboembolism recurrence after discontinuation of low molecular weight heparin treatment for cancer-associated thrombosis (HISPALIS-study). Cancers (Basel) 2022;14:2771. DOI: https://doi.org/10.3390/cancers14112771
16. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. Br J Cancer 2018;119:915-21. DOI: https://doi.org/10.1038/s41416-018-0269-5
17. Khorana AA, Kamphuisen PW, Meyer G, et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. J Clin Oncol 2017;35:1078-85. DOI: https://doi.org/10.1200/JCO.2016.67.4564
18. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012;126:448-54. DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.051920
19. den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 2013;11:998-1000. DOI: https://doi.org/10.1111/jth.12192
20. Astruc N, Ianotto JC, Metges JP, et al. External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis. Eur J Intern Med 2016;36:e11-e2. DOI: https://doi.org/10.1016/j.ejim.2016.08.001
21. Delluc A, Miranda S, Exter PD, et al. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica 2020;105:1436-42. DOI: https://doi.org/10.3324/haematol.2019.222828
22. Girard P, Laporte S, Chapelle C, et al. Failure of the Ottawa Score to Predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study. Thromb Haemost 2022;122:151-7. DOI: https://doi.org/10.1055/a-1486-7497
23. Munoz AJ, Souto JC, Lecumberri R, et al. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. Thromb Res 2023;228:181-8. DOI: https://doi.org/10.1016/j.thromres.2023.06.015
24. Lanting VR, Takada T, Bosch FTM, et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost 2025;125:589-96. DOI: https://doi.org/10.1055/a-2418-3960
25. Vedovati MC, Munoz Martin AJ, Giustozzi M, et al. Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism. Eur J Intern Med 2025;137:67-72. DOI: https://doi.org/10.1016/j.ejim.2025.04.016
26. van Dam LF, Dronkers CEA, Gautam G, et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood 2020;135:1377-85. DOI: https://doi.org/10.1182/blood.2019004114
27. Potere N, Giulianelli M, Candeloro M, et al. Non-invasive characterization of lower extremity deep vein thrombosis via advanced ultrasound elastography: a prospective pilot study. Intern Emerg Med 2025;20:2411-20. DOI: https://doi.org/10.1007/s11739-025-04135-7
28. Schaefer JK, Li M, Wu Z, et al. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. J Thromb Haemost 2021;19:212-20. DOI: https://doi.org/10.1111/jth.15153
29. Swan D, Turner R, Grove EL, et al. Direct oral anticoagulant failure in patients with venous thromboembolism-why and what next? J Thromb Haemost 2025;23:1774-86. DOI: https://doi.org/10.1016/j.jtha.2025.03.026
30. Potere N, Mahe I, Angchaisuksiri P, et al. Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey. J Thromb Haemost 2024;22:1973-83. DOI: https://doi.org/10.1016/j.jtha.2024.03.019
31. Poenou G, Toledano E, Helfer H, et al. Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events. Front Cardiovasc Med 2023;10:1132156. DOI: https://doi.org/10.3389/fcvm.2023.1132156
32. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023;34:452-67. DOI: https://doi.org/10.1016/j.annonc.2022.12.014
33. Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009;7:760-5. DOI: https://doi.org/10.1111/j.1538-7836.2009.03326.x
34. Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res 2014;134:93-5. DOI: https://doi.org/10.1016/j.thromres.2014.04.028
35. Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost 2015;13:1010-8. DOI: https://doi.org/10.1111/jth.12955
36. Lanting VR, Bosch FTM, Martens ESL, et al. Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. J Thromb Haemost 2025;23:332-9. DOI: https://doi.org/10.1016/j.jtha.2025.08.022
How to Cite
1.
Di Nisio M, Wang T-F. Prediction and management of recurrent venous thromboembolism in patients with cancer. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Oct. 18];5(s1). Available from: https://www.btvb.org/btvb/article/view/419
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
